Clinical Trials Logo
  1. Home
  2. Acute Lymphocytic Leukemia
  3. NCT01310946
  4. Details
NCT01310946 Clinical Trial

Establishment of Acute Lymphocytic Leukemia Data Base in the Department of Oncology

Acute Lymphocytic Leukemia Clinical Trial

Official title:
Establishment of Acute Lymphocytic Leukemia Data Base in the Department of Oncology

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT01310946
Other study ID # RAC# 2021-051
Secondary ID RAC# 2021-051
Status Recruiting
Phase N/A
First received March 6, 2011
Last updated December 11, 2011
Start date June 2003

Study information
Verified date December 2011
Source King Faisal Specialist Hospital & Research Center
Contact N Chaudhri, M.D.
Phone +966-1-4423949
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

Establishment of Acute Lymphocytic Leukemia Data Base in the Department of Oncology

Description:

Establishment of Acute Lymphocytic Leukemia Data Base in the Department of Oncology

Recruitment information / eligibility
Status Recruiting
Enrollment 203
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 14 Years to 85 Years
Eligibility Inclusion Criteria:

- Patients with diagnosed Acute Lymphocytic Leukemia

Exclusion Criteria:

- Patients with diagnosis other than Acute Lymphocytic Leukemia

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Intervention

Other:
• Database
Database

Locations
Country Name City State
Saudi Arabia Kfsh & Rc Riyadh

Sponsors (1)
Lead Sponsor Collaborator
King Faisal Specialist Hospital & Research Center

Country where clinical trial is conducted

Saudi Arabia, 

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03755414 - Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation Phase 1
Withdrawn NCT05170828 - Cryopreserved MMUD BM With PTCy for Hematologic Malignancies Phase 1
Recruiting NCT02892695 - PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma Phase 1/Phase 2
Active, not recruiting NCT01430390 - In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies Phase 1
Terminated NCT01551043 - Allo CART-19 Protocol Phase 1
Completed NCT00975975 - Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer Phase 2
Completed NCT00098033 - Investigation of Clofarabine in Acute Leukemias Phase 2
Terminated NCT00852709 - Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias Phase 1
Completed NCT01930162 - Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant Phase 2
Completed NCT02581007 - Reduced Intensity Conditioning Transplant Using Haploidentical Donors Phase 2
Terminated NCT01745913 - Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies Phase 2
Completed NCT03263637 - Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies Phase 1
Withdrawn NCT05201183 - A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies Phase 1/Phase 2
Recruiting NCT02819583 - CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma Phase 1/Phase 2
Completed NCT00990587 - Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy Phase 1
Completed NCT00854646 - Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS) Phase 1
Terminated NCT00594308 - In-Vivo Activated T-Cell Depletion to Prevent GVHD N/A
Completed NCT00773149 - Alemtuzumab (CAMPATH 1H) Associated to G-CSF in Adult Patients With Refractory Acute Lymphocytic Leukemia Phase 1/Phase 2
Recruiting NCT00271063 - Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute Lymphocytic Leukemia Phase 1/Phase 2
Completed NCT01272817 - Nonmyeloablative Allogeneic Transplant N/A